Retrophin (NASDAQ:RTRX) Downgraded by BidaskClub

BidaskClub cut shares of Retrophin (NASDAQ:RTRX) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports.

A number of other research analysts also recently weighed in on RTRX. ValuEngine upgraded Retrophin from a hold rating to a buy rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded Retrophin from a hold rating to a strong-buy rating and set a $14.00 price target on the stock in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $27.75.

Shares of NASDAQ RTRX opened at $13.87 on Tuesday. The company has a quick ratio of 4.94, a current ratio of 5.00 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $609.95 million, a price-to-earnings ratio of -5.46 and a beta of 0.86. The stock’s fifty day simple moving average is $13.84 and its 200 day simple moving average is $15.11. Retrophin has a 52-week low of $10.87 and a 52-week high of $24.69.

Retrophin (NASDAQ:RTRX) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.10) by $0.55. Retrophin had a negative return on equity of 43.88% and a negative net margin of 71.70%. The business had revenue of $44.37 million for the quarter, compared to analysts’ expectations of $45.31 million. During the same period in the previous year, the firm posted ($0.68) EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. As a group, analysts anticipate that Retrophin will post -3.45 earnings per share for the current year.

In other news, Director Steve Aselage sold 5,000 shares of Retrophin stock in a transaction on Friday, November 29th. The stock was sold at an average price of $13.91, for a total transaction of $69,550.00. Following the transaction, the director now owns 250,966 shares in the company, valued at $3,490,937.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.32% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new position in Retrophin in the second quarter valued at about $26,000. Meeder Asset Management Inc. grew its stake in Retrophin by 641.4% in the third quarter. Meeder Asset Management Inc. now owns 4,011 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 3,470 shares in the last quarter. Cutler Group LP purchased a new position in Retrophin in the third quarter valued at about $70,000. Zebra Capital Management LLC purchased a new position in Retrophin in the third quarter valued at about $122,000. Finally, Russell Investments Group Ltd. grew its stake in Retrophin by 117.7% in the third quarter. Russell Investments Group Ltd. now owns 24,700 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 13,355 shares in the last quarter.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What is Cost of Debt?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit